PROK — PROKIDNEY CORP.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1850270 ·
Last close
$1.10
Market Cap
$229.87M
52W High
$2.65
52W Low
$0.87
ADV30
1,367,041
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 174,000 | — | -53,758,000 | -35,592,000 | 210,279,000 | 81,355,000 | 33,304,000 |
| Jun 2026 | 150,000 | — | -48,373,000 | -28,422,000 | 249,016,000 | 74,868,000 | 26,178,000 |
| Mar 2026 | 226,000 | — | -44,933,000 | -20,037,000 | 292,784,000 | 101,895,000 | 29,680,000 |
| Dec 2025 | 225,000 | — | -45,371,000 | -19,231,000 | 335,574,000 | 108,537,000 | 34,781,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-141,167,000
Investing CF
$104,744,000
Financing CF
$26,351,000
CapEx
$-18,567,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.54
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,318,294,000
Inventory
—
Receivables
$956,000
ST Investments
$106,696,000
EBIT TTM
$-166,758,000
Pretax Income TTM
$-166,777,000
Interest Exp TTM
$19,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$775,000
EBITDA
$-185,907,008
Free Cash Flow
$-86,582,872
Enterprise Value
$1,164,281,856
Total Cash
$141,864,000
Total Debt
$3,253,000
Shares Out
208,975,486
Trailing EPS
$-0.50
Book Value
$-4.34
ROE
-73.4%
ROA
-42.9%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 893,000 | -165,007,000 | -68,986,000 | 335,574,000 | 34,781,000 | -1,011,197,000 | -120,117,000 |
| Dec 2024 | 76,000 | -183,676,000 | -61,186,000 | 441,073,000 | 39,436,000 | -994,954,000 | -126,351,000 |
| Dec 2023 | 0 | -151,522,000 | -35,468,000 | 420,552,000 | 29,216,000 | -1,103,396,000 | -90,069,000 |
| Dec 2022 | 0 | -153,007,000 | -108,032,000 | 517,996,000 | 13,057,000 | -1,096,616,000 | -77,089,000 |
TTM Snapshot
Revenues TTM
$818,000
NetIncome TTM
$-84,159,000
OpCashFlow TTM
—
Assets (Latest)
$249,016,000
Forward EPS
$-0.77
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $1.00 · spot: $1.04 · call volume: 202 · put volume: 92Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LXEO | Lexeo Therapeutics, Inc. | $234.24M | $2.86 | — |
| CABA | Cabaletta Bio, Inc. | $220.03M | $1.02 | — |
| PLX | Protalix BioTherapeutics, Inc. | $242.84M | $2.88 | — |
| IPSC | Century Therapeutics, Inc. | $248.79M | $1.37 | — |
| LCTX | Lineage Cell Therapeutics, Inc. | $206.36M | $0.82 | — |
News headlines (Yahoo Finance, 1h cache)
ProKidney Names Farah Ali, M.D., M.S., Chief Medical Officer
2026-11-18 21:15 · Yahoo
ProKidney Corp. (PROK) Reports Q3 Loss, Misses Revenue Estimates
2026-11-12 22:05 · Yahoo
ProKidney Reports Third Quarter 2026 Financial Results and Business Highlights
2026-11-12 21:10 · Yahoo
ProKidney Targets Q2 2027 Phase III Readout as Rilparencel Enrollment Surpasses 500
2026-10-28 10:03 · Yahoo
ProKidney to Host Virtual KOL Event to Recap Mechanism of Action Data Presented at ASN Kidney Week and Provide a Corporate Update
2026-10-22 12:45 · Yahoo
ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026
2026-10-22 12:00 · Yahoo
ProKidney (PROK) Nears A Pivotal Kidney Therapy Verdict
2026-09-11 05:28 · Yahoo
Why ProKidney (PROK) Is Building Its Bull Case Around Rilparencel’s Accelerated Approval Path
2026-06-17 15:16 · Yahoo
ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates
2026-05-15 16:55 · Yahoo
ProKidney Reports First Quarter 2026 Financial Results and Business Highlights
2026-05-15 15:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.